From Poster board: Brilacidin is being developed
Post# of 72447
(Total Views: 353)
Posted On: 11/13/2018 8:36:16 AM
From Poster board:
Brilacidin is being developed as a novel, non-corticosteroid, nonbiologic treatment for Inflammatory Bowel Disease (IBD), with formulation development plans including oral tablets for the treatment of Ulcerative Colitis and Crohn’s Disease, and foam and/or gel for the treatment of mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD. Brilacidin is a fully synthetic, non-peptidic, Host Defense Protein (HDP) mimetic with a molecular weight (free base) of 936.9 g/mol.
HDPs, also referred to as defensins, isolated from organisms across the phylogenetic spectrum form part of an innate immune system and serve as the first line of defense against microbial infection in many species. HDPs are typically small (12-80 amino acids) cationic amphipathic proteins that provide protection against a wide variety of pathogenic organisms. Apart from the ability of HDPs to kill bacteria by direct action (by both membrane and nonmembrane effects), they have a potential role in modulation of multiple cellular immune and inflammatory responses.
Brilacidin appears to be anti-inflammatory based largely on its inhibition of phosphodiesterases (PDE4 and PDE3) and its down regulation of pro-inflammatory cytokines. The drug candidate, which to date has been evaluated in clinical trials in three indications (serious skin infections, oral mucositis, IBD), also has antibacterial activity with a predominantly gram-positive spectrum. The current clinical study was initiated to examine efficacy, safety and PK in treatment of UP/UPS when administered locally as a retention enema.
Brilacidin is being developed as a novel, non-corticosteroid, nonbiologic treatment for Inflammatory Bowel Disease (IBD), with formulation development plans including oral tablets for the treatment of Ulcerative Colitis and Crohn’s Disease, and foam and/or gel for the treatment of mild-to-moderate Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of IBD. Brilacidin is a fully synthetic, non-peptidic, Host Defense Protein (HDP) mimetic with a molecular weight (free base) of 936.9 g/mol.
HDPs, also referred to as defensins, isolated from organisms across the phylogenetic spectrum form part of an innate immune system and serve as the first line of defense against microbial infection in many species. HDPs are typically small (12-80 amino acids) cationic amphipathic proteins that provide protection against a wide variety of pathogenic organisms. Apart from the ability of HDPs to kill bacteria by direct action (by both membrane and nonmembrane effects), they have a potential role in modulation of multiple cellular immune and inflammatory responses.
Brilacidin appears to be anti-inflammatory based largely on its inhibition of phosphodiesterases (PDE4 and PDE3) and its down regulation of pro-inflammatory cytokines. The drug candidate, which to date has been evaluated in clinical trials in three indications (serious skin infections, oral mucositis, IBD), also has antibacterial activity with a predominantly gram-positive spectrum. The current clinical study was initiated to examine efficacy, safety and PK in treatment of UP/UPS when administered locally as a retention enema.
(5)
(0)